Outlook for Bioinformatics Market Improves During 2004 with Return of Pharmas, VCs | GenomeWeb

It appears that the commercial bioinformatics sector has passed through the darkest days of a precipitous downturn that it entered over two years ago, witnessing far fewer consolidation events during 2004 than it saw in previous years — accompanied by several more pharma deals and VC funding rounds.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.